| Company Name | 缅北禁地. |
|---|---|
| Date Established | December 6, 1941 |
| Head Office | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan |
| Telephone | 81-3-3817-3700 |
| Representatives | Haruo Naito, Representative Corporate Officer and CEO
Yasushi Okada, Representative Corporate Officer Keisuke Naito, Representative Corporate Officer and Executive Vice President |
| Capital | 44,986 million Yen (as of March 31, 2024) |
| Scope of Business | Research and development, manufacture, sale and import and export of pharmaceuticals |
| Organization Chart | |
| Employees | Consolidated : 11,067
Non-Consolidated : 2,984 (as of March 31, 2024) |
| Production Plants | Kawashima Industrial Park (Gifu Prefecture)
Kashima Plant (Ibaraki Prefecture) Eisai Manufacturing Ltd. (U.K.) Eisai China Inc. Suzhou Plant (China) Eisai (Liaoning) Pharmaceutical Co., Ltd. Benxi Plant (China) Eisai Pharmaceuticals India Pvt. Ltd. (India), etc. |
| Laboratories | Tsukuba Research Laboratories (Ibaraki Prefecture)
Kawashima Industrial Park (Gifu Prefecture) Kashima Business Office (Ibaraki Prefecture) Kobe Research Laboratories (Hyogo Prefecture) Eisai Center for Genetics Guided Dementia Discovery (G2D2) (U.S.A.) Exton Site (U.S.A.) Hatfield Research Institute (U.K.), etc. |
| Overseas Sales Offices | Eisai Inc. (U.S.A.)
Eisai Ltd. (U.K.) Eisai GmbH (Germany) Eisai S.A.S. (France) Eisai China Inc. (China) Eisai Korea Inc. (South Korea), etc. |
Stock Information
| Fiscal Year End | March 31 |
|---|---|
| Record Date for Dividend | Year-end dividend - March 31
Interim dividend - September 30 |
| Annual Shareholders' Meeting | June |
| Stock Exchange Listings | Tokyo Stock Exchange |
| Stock Trading Unit | 100 shares |
| Ticker Code | 4523 |
